nach oben

Drugs

Erschienen in:

01.09.2008 | Adis Drug Profile

Budesonide/Formoterol Pressurized Metered-Dose Inhaler

verfasst von: Katherine A. Lyseng-Williamson, Dene Simpson

Erschienen in: Drugs | Ausgabe 13/2008

Einloggen, um Zugang zu erhalten

Abstract

▲ The corticosteroid budesonide and the long-acting β₂-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients aged ≥12 years with asthma.
▲ In well designed 12-week clinical trials in patients with mild to moderate or moderate to severe persistent asthma, lung function improved to a significantly greater extent with twice-daily budesonide/formoterol pMDI 160 µg/9 µg or 320 µg/9 µg than with placebo or the same nominal dosage of either of the components alone.
▲ Budesonide/formoterol pMDI was also associated with improvements from baseline in patient-reported asthma control, asthma symptom and asthma-related quality of life outcomes that were significantly greater than those with placebo and, for many endpoints, monotherapy with the individual components.
▲ In a 52-week safety study, treatment with twice-daily budesonide/formoterol pMDI 320 µg/9 µg was associated with rapid and durable improvements in lung function and asthma control that were significantly greater than those with twice-daily budesonide pMDI 640 µg monotherapy.
▲ Budesonide/formoterol pMDI was well tolerated in clinical trials. Its overall adverse event profile is consistent with the known tolerability profiles of long-acting β₂-adrenoceptor agonist and inhaled corticosteroid therapy, and is similar to that shown with placebo.

The use of trade names is for product identification purposes only and does not imply endorsement.

Guidelines for the diagnosis and management of asthma: summary report 2007. Bethesda (MD): National Heart, Lung, and Blood Institute; 2007 Oct

Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β₂-agonists and corticosteroids. Eur Respir J 2002; 19(1): 182–91PubMedCrossRef

Symbicort® (budesonide and formoterol fumarate dihydrate) inhalation aerosol: US prescribing information. Wilmington (DE): AstraZeneca LP, 2007 Oct

Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64(14): 1597–618PubMedCrossRef

McCormack PL, Lyseng-Williamson KA. Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma. Drugs 2007; 67(16): 2407–31PubMedCrossRef

Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44(3): 375–407PubMedCrossRef

Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 Jul; 42(1): 115–37PubMedCrossRef

Remington TL, DiGiovine B. Long-acting β-agonists: anti-flammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 2005 Jan; 11(1): 74–8PubMedCrossRef

Capraz F, Kunter E, Ilvan A, et al. The effect of inhaled budesonide and formoterol on bronchial remodeling in young asthmatics [abstract no. P1243]. Eur Respir J Suppl 2006 Sep; 28 Suppl. 50: 208s

10.

Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005 Oct; 128(4): 1936–42PubMedCrossRef

11.

Hampel FC, Martin P, Mezzanotte S. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. J Asthma 2008 May; 45(4): 265–72PubMedCrossRef

12.

Kaiser HB, Miller CJ, O’Dowd L. Measured onset of bronchodilation with budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) in patients with asthma previously receiving inhaled corticosteroids [abstract no. 974]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl.): S249CrossRef

13.

Adner M, Cardell L-O, Naya MI, et al. Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol and terbutaline but not salmeterol in mouse trachea [abstract]. Am J Respir Crit Care Med 2007; 175 Suppl. 1: A463

14.

Corren J, Korenblat PE, Miller CJ, et al. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 2007 May; 29(5): 823–43PubMedCrossRef

15.

Noonan M, Rosenwasser LJ, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial [published erratum appears in Drugs 2007; 67 (5): 759]. Drugs 2006; 66(17): 2235–54PubMedCrossRef

16.

Peters SP, Prenner BM, Mezzanotte WS, et al. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc. Epub 2008 Aug 8

17.

Ankerst J, Lotvall J, Tronde A, et al. Pharmacokinetics and systemic bioavailability of budesonide (BUD) and formoterol (FM) administered via one pressurized metered-dose inhaler (pMDI) in adults and children with asthma [abstract]. Am J Respir Crit Care Med 2007; 175 Suppl. 1: A192

18.

Ankerst J, Lotvall J, Tronde A, et al. Systemic bioavailability of budesonide (BUD) and formoterol (FM) administered via one pressurized metered-dose inhaler (pMDI) in asthma patients and healthy subjects [abstract]. Am J Respir Crit Care Med 2007; 175 Suppl. 1: A192

19.

Morice AH, Peterson S, Beckman O, et al. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007 Nov; 61(11): 1874–83PubMedCrossRef

20.

Murphy K, Nelson H, Parasuraman B, et al. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Curr Med Res Opin 2008; 24(3): 879–94PubMedCrossRef

21.

Chervinsky P, Baker J, Bensch G, et al. Improvement in health-related quality of life (HRQL) after use of budesonide (BUD) and formoterol (FM) in one pressurized metered-dose inhaler (pMDI) in adults with moderate to severe asthma [abstract]. Am J Respir Crit Care Med 2007; 175 Suppl. 1: A781

22.

Baker J, Martin P, Parasuraman B. Patient satisfaction with budesonide and formoterol in one pressurized metered-dose inhaler in patients with asthma [abstract]. Chest 2007 Oct; 132 (4 Suppl.): 509S

23.

Morice AH, Hochmuth L, Ekelund J, et al. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler® in adolescents and adults with asthma. Pulm Pharmacol Ther 2008 Feb; 21(1): 32–9PubMedCrossRef

Titel: Budesonide/Formoterol Pressurized Metered-Dose Inhaler
verfasst von: Katherine A. Lyseng-Williamson
Dene Simpson
Publikationsdatum: 01.09.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 13/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868130-00005

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Budesonide/Formoterol Pressurized Metered-Dose Inhaler

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2008

Febuxostat

HMG-CoA Reductase Inhibitors

Anaesthetic Drugs and Defibrillation Threshold Testing

Febuxostat

Approved and Investigational Uses of Modafinil

Local Treatment of Vulvovaginal Candidosis